All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2017-04-18.
From the record
Globus Medical Inc's filings since 2017 show 2 warning events of 2 kinds: an auditor change (8-K item 4.01, the latest 2017-04-18); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2017-03-01) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+20.1% a year over 10 filed years; profitable in 10 of 10.
From the record
Globus Medical Inc's 10 filed years say what it did: revenue went from $564 million in fiscal 2016 to $2.9 billion in fiscal 2025, up 20.1% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 10 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count grew 10.1% a year. 40% of cash flow returned. Insiders: 13 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, Globus Medical Inc's diluted share count grew about 10.1% a year, and dividends and buybacks returned about 40% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 13 sales (8 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 12%: 12¢ of profit per shareholder dollar. Leverage 14%: owes 14¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Globus Medical Inc earned about 12 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 37 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 14 cents per dollar of assets, and net share issuance: its share count shrank 0.6% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 12% of 109 in its family; net margin 18.3%.
From the record
Globus Medical Inc's standing among 109 graded names in its industry family: revenue of $2.9 billion in fiscal 2025 ranks in the top 11% by size; a net margin of 18.3% ranks in the top 8%; revenue growth of 42.2% a year over the last 3 filed years ranks in the top 18% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 45% of 91 in its family for leadership; chief executive since 2025.
From the record
Globus Medical Inc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Pfeil, Keith W (President, CEO, as filed), filing under that title since 2025-08-27, 1.2 years (bottom 27% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 7.5 years (top 21%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (top 42%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 43% of 104 in its family for room to expand.
From the record
Globus Medical Inc's room to grow, from the newest filed statements (fiscal 2025): cash of $526 million against no long-term debt tagged leaves 9.9% of its assets as net cash, bottom 47% of its family; cash from operations less capital spending is 20% of revenue (top 8%); a gross margin of 67.4% (top 37%); research spending of 5% of revenue (bottom 24%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 20% of 105 in its family for growth drivers.
From the record
Globus Medical Inc's growth drivers, from the filed years to fiscal 2025: revenue grew 42.2% a year over the last three filed years against 20.1% over all 10, speeding up (top 8% of its family); the newest year grew 16.7% (top 38%); research spending grew 26.3% a year (top 18%); capital spending grew 30.5% a year (top 15%) (its annual reports). Globus Medical Inc reported 2 product lines in fiscal 2025: Musculoskeletal Solutions at $2.8 billion (95%), Enabling Technologies at $141 million (5%); 1 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 46% of 88 in its family for expectations against reality.
From the record
Globus Medical Inc's newest year against its own record: revenue of $2.9 billion in fiscal 2025 came in 25.6% below the $4.0 billion its prior three years' pace pointed to (bottom 17% of its family); net income of $538 million against a prior three-year average of $139 million (top 4%); a net margin of 18.3% against 10.2% before (bottom 47%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made